Introduction
Patients with cystic fibrosis (CF) often have peripherally inserted central catheters (PICC) or totally implantable venous access devices (TIVAD) to provide convenient access for the administration of parenteral antibiotics and to reduce pain and discomfort. Although these provide easy access, both PICC and TIVAD use may be complicated by thrombus formation. Deerojanawong et al 1 reported that 19% of the children in their study developed clots associated with TIVAD. In view of the fact that the presence of PICC or TIVAD may provide a focus for thrombus development, it is also important to establish whether patients with CF are more at risk of thrombotic episodes than the general population.
There is limited information on thrombophilia tendency in CF and whether it contributes to clotting with TIVAD. [2] [3] [4] [5] The only 2 full articles published have shown an increased incidence of thrombophilia in patients with CF. Because of these reports of reductions in the levels of natural antithrombotic proteins, we wished to establish whether our CF population showed a similar thrombophilic tendency, particularly in view of the fact that only one thrombotic episode had been noted in the past in our group. We chose the following thrombophilic markers, protein C, protein S, antithrombin III, activated protein C resistance, and the presence of a lupus anticoagulant to compare our results with previously reported studies.
Patients and Methods
Thirty five females and 36 males, aged 1 to 19 years were investigated. Institutional ethics approval was given for the study and consent obtained from participants. All CF patients attending hospital over a period of 14 months for routine annual reviews (30%), or hospitalized for treatment (70% in an exacerbated state), were included in the study. When a second specimen was available from a patient within the 14-month study period, the results were included in the analyses, the majority of these were in excess of 6 months from the original specimen.
Of the study group, 59% were homozygous for the F508del mutation, 35% were heterozygous for the F508del mutation in combination with some other severe group I-III allele, while 5% had an assortment of other mutations.
Routine coagulation profiles (prothrombin time and activated partial thromboplastin time [APTT]) are checked at regular intervals in these patients. These routine tests were then extended to include the most common thrombophilia factors. No extra blood was required to carry out the tests.
Antithrombin and protein C functional activity were assayed using Stachrom kits from STAGO diagnostics (Asnieres, France) and protein S (free antigen percentage) was estimated with the STAGO Liatest S kit. Activated protein C resistance was determined using the Gradileiden V kit from Life Diagnostics (Clarkston, GA). The presence of a lupus anticoagulant was determined using an APTT, kaolin clotting time (KCT; laboratory prepared, 0.05% kaolin), and dilute Russell's viper venom time (DRVVT) Screen (and Confirm where appropriate; Life Diagnostics). All tests were performed on a STAGO Compact coagulation analyser.
Antithrombin and proteins C and S were calculated as a percentage against a WHO-calibrated standard plasma. Activated protein C resistance was initially screened, and if positive, a gene analysis was performed. The screen for a lupus anticoagulant was considered positive with prolongation of both the KCT and DRVVT (with or without confirmation by additional phospholipid).
The reference ranges used to indicate an abnormal result in this study are consistent with those employed by Balfour-Lynn et al 4 : antithrombin <70%; protein C <70%, and protein S <65%. The age-adjusted ranges of Andrews et al 6 The patients were not specifically examined for the presence of a thrombus, however, the appearance of clinical symptoms or blocked lines during the period of the study were the triggers for investigation.
Those patients considered to have a lupus anticoagulant, reduced protein C, protein S, or antithrombin III value were combined as a single group and compared against the nonthrombophilic group (Table 1) , for a number of criteria.
Results
Our preliminary observation of an increased incidence of lupus anticoagulants compared to those seen in the general population was confirmed. Eighteen percent (15/71) of the patients showed a lupus anticoagulant, far in excess of that expected in the general population, at less than 8% 8 ( Table 2) . Of these, 8 had repeat testings, with 2 showing a consistent finding of a lupus anticoagulant at least 12 months apart. Of the 15, 2 showed some minor liver dysfunction (borderline ALP) with 1 of these having a consistent finding of a lupus anticoagulant.
The number of patients with reduced protein C activity (10/71; 14%) was far in excess of the 0.5% expected from the general population 9 ( Table 2 ). The reduced protein C activities obtained ranged from 46% to 68%. Five of the patients had repeat assays with only 1 showing a consistent reduction in protein C level over a 9-month period. Of the 10 patients, 3 showed some liver dysfunction and these coincided with a low protein C at that testing. A single patient was investigated on 3 occasions. On one occasion all test were completely normal, the second showed an abnormal liver function, and the third showed both a low protein C and liver dysfunction.
A reduction in protein S free antigen was found in 19.7% of the patients (14/71) again far in excess of that expected in the general population. 10 There was a similar incidence in both the males and females. The reduced protein S free antigen percentages ranged from 41% to 63%. Of these patients, 9 had repeat studies at least 3 months apart and of these, only 1 showed a consistent depression in protein S level. Of the 14 patients, 3 had liver dysfunction but only 1 of these was at a test when the protein S level was also low. A single patient had quite deranged liver function tests and a low protein S value, however, this patient had a quite normal protein C level, questioning whether liver dysfunction is responsible for the reduction in protein S levels.
The incidence of antithrombin deficiency in the general population (0.02-0.17%) 11 is much lower than the incidence of protein C or protein S deficiency, and this was reflected in the study with no antithrombin deficiencies being detected.
Three patients were found to have activated protein C resistance (4.2%), which is within expected limits for the general population. 12 All 3 were heterozygous for the factor V Leiden mutation. Of the 3 patients, 2 were siblings.
Multiple abnormalities were seen in 10 patients. Two patients showed a reduced protein S free antigen percentage in conjunction with a lupus anticoagulant, while 4 patients had both a protein C reduction and lupus anticoagulant. Four patients had a deficiency of both protein C and S, and of these only 1 showed any liver dysfunction.
No correlation appeared to exist between the development of a lupus anticoagulant and either the age or sex of the patient. There was an increased number of the patients with a lupus anticoagulant who were also positive for Pseudomonas aeruginosa, suggesting a possible infective basis for this phenomenon. The use of age-dependent ranges 6,7 produced a considerable change in the percentage of patients showing a protein C, protein S, or antithrombin III deficiency ( Table 3 ).
There were no criteria that would appear to predispose the patients to a thrombophilic tendency ( Table 1) . No clinically evident thrombotic episodes were recorded during the study period, and in fact, among the study group, a single pulmonary embolus at least 3 years prior to the study was the only instance of a clinically significant thrombotic event.
No PICC or TIVAD required removal due to blockage or thrombosis over the 14-month period, and no other interventions such as tissue plasminogen activator administration were required.
Discussion
We have confirmed an increased incidence of thrombophilia in our group of CF patients. The activated protein C resistance incidence was comparable with population norms, with 3 of the 71 patients (4%) proving to be heterozygous for the factor V Leiden mutation. Of these 3 patients, 2 were siblings.
An increased number of lupus anticoagulants have been found compared with the previous studies, 4,5 although it is difficult to determine whether the discrepancy is coincidental or truly reflects a difference perhaps related to geography, ethnicity, or methodology. Transient lupus anticoagulants often arise in the pediatric population post infection 13, 14 and in those patients with a lupus anticoagulant, 73% were positive for P aureginosa while only 46% were positive in the remaining patients. However, whether infection alone explains the number of lupus positive patients in our CF children is unknown. The increased number may also reflect minor immunological perturbations or it may be dependent on drug exposure. Two of the patients had a consistent finding of a lupus anticoagulant. Although the thrombotic potential of a transient lupus may be questionable, a patient with a consistent finding of a lupus anticoagulant must be considered at increased likelihood of a thrombotic event. This would be particularly true of a patient who also has the additional risk factor of a line being inserted.
Protein C levels were reduced in 14% of cases. The percentage of our CF patients with a protein C deficiency is far in excess of previous studies ( Table 2 ). The reduction in activity is acquired and not genetically determined as those patients who have had multiple tests have shown variable results with only 1 of the 5 patients with repeat tests having a consistently low protein C level. Typical of the inconsistent results was a patient with a protein C level of 53% at 1 test and 93% some 8 months later.
The percentage of patients with a reduced protein S result (19.7%) also exceeded that found in the previous studies (5%), but all the studies have shown a considerably increased percentage over the population norm of approximately 0.3%. These reduced levels are again most likely acquired, since variability has been found, with protein S values rising from an abnormal level of 59% to a normal 72% in the 1 patient 11 months later. Nine patients with low protein S levels had repeat tests with only 1 of these showing a consistently low protein S level.
In this study, there was no evidence of an antithrombin deficiency unlike Balfour-Lynn et al 4 and Van Konnigsbruggen et al 2 (1% and 2%, respectively). Thus the abnormal protein levels were found in both the gammacarboxylated proteins. There was no evidence to support liver dysfunction as the cause of the reduced levels. In the group of patients with a reduced C and or S, 58% of them also had a reduction in vitamin A, D, or E or a combination of these. However, of the group that did show abnormal vitamin values, 60% did not show any evidence of a reduction in protein C or S levels. Vitamin K levels were not directly measured and while there may be a disparity in the vitamin K sensitivity between the procoagulant vitamin K dependent factors and protein C and S, not 1 patient had a prolonged prothrombin time or extended APTT suggestive of a vitamin K deficiency.
The use of age-dependent ranges is recommended in a paediatric laboratory. The dramatic difference in the number of deficient patients for each parameter using age-dependent ranges ( Table 3 ) illustrates the importance of these ranges. However a result of either 2.8% or 30% of the patients showing an antithrombin deficiency depending on the agedependent range employed, serves as a warning that the use of published ranges can bring about an uncertain result and ranges established within an institution are most appropriate.
The results do indicate though that the patients may undergo periods where they have reduced levels of protein C or S or both and also transient lupus anticoagulants. The exact cause of these transitory findings is uncertain at this stage.
Although thrombophilia appears to be a real risk factor in CF patients, there would be questionable clinical benefit in screening for this as a prelude to placing a catheter or TIVAD. There are a number of reports describing patients with CF having thrombotic episodes possibly associated with line insertion. 3, 15, 16 We do not know the thrombophilia status of the patients in those studies, but it is possible that they were at greater risk of developing a thrombus than the general patient population. Of our patients, 10 had a TIVAD placed, with another 35 having a PICC (Table 1) , with only the 1 reported thrombotic episode in a child with a PICC line in situ, when a pulmonary embolus developed, some 3 years prior to the study. In fact, in this study, TIVADs were placed in nearly twice as many thrombophilic as nonthrombophilic patients without incident. We cannot however exclude the possibility that asymptomatic events did occur in our group.
We do not know at this stage why the CF patients have reduced anticoagulant levels or a lupus anticoagulant. The appearance of a lupus anticoagulant, protein C, or protein S reduction did not appear to be related to the CF genotype, nor to liver dysfunction, with the nonthrombophilic group having a similar percentage of cases of abnormal liver enzyme results. Lupus anticoagulants are reported to induce activated protein C resistance, 17 while a direct effect on protein S 18 and protein C levels is less certain. In our series of patients, if a lupus anticoagulant was responsible for a reduction in protein C and S levels it would only explain 20% of the protein S cases and 40% of those with a reduced protein C level. There is evidence to support the involvement and possible consumption of protein C and protein S as a result of an inflammatory process [19] [20] [21] [22] and this may be a more likely explanation. Of interest is the fact that 11 of the 14 patients with reduced protein S levels were positive for Pseudomonas aureginosa or Staphlococcus aureus.
This study has confirmed previous findings, however, with the percentages obtained for each of the parameters considered being higher than previous observations ( Table 2) . A further study is proposed to assess other thrombophilic markers and determine the status of inflammatory markers in these patients. In view of the fact that only 1 patient developed a thrombus (outside the study period) there would appear to be little advantage in mass screening of the cystic population. It is still unknown if these patients have asymptomatic thromboses, however, should a thrombus be detected, it would be reasonable to screen for a thrombophilic tendency. If screening does occur, it is most important, in view of the apparent transient nature of the protein C and S deficiencies and lupus anticoagulant presence, that repeat tests on at least a further 2 occasions are performed, preferably 2 to 3 months apart, to determine if the results are transient or consistent findings. This should avoid any patients being mislabeled as thrombophilic.
